Animal experimental research of intralesional bleomycin and pingyangmycin in the treatment of xanthoma. (7th October 2021)

• Record Type: Journal Article
• Authors: Lin, Xian‐zh; Hu, Hao; Zhao, Xu; Qian, Yu‐x; Wang, Hui; Jiang, Hua; Zhu, Lie
• Is Part Of: Journal of cosmetic dermatology. Volume 21:Number 7(2022)
• Page Start: 2977
• Page End: 2983
• Publication Date: 2021-10-07
• Subjects: bleomycin -- intralesional injections -- pingyangmycin -- xanthelasma palpebrarum; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.14500
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: Background: Xanthelasma palpebrarum is a type of human xanthoma that occurs on the skin of human eyelids and is a benign skin lesion. Pingyangmycin (also known as bleomycin A5) is one of the 13 components of bleomycin. The aim of this study was to explore the efficacy of intralesional bleomycin and pingyangmycin in the treatment of xanthoma based on histopathological observations in animal experimental research. Methods: An animal model of xanthoma was established by feeding rabbits with a high‐cholesterol diet. Pingyangmycin and bleomycin interfered with the skin xanthoma of the animal model. Skin tissue specimens were stained with hematoxylin‐eosin and oil red O to evaluate the effect of the intervention. Results: A xanthoma animal model was established. Pingyangmycin and bleomycin could reduce the abnormal lipid deposition in the lesion area of the skin xanthoma of the animal, via a local injection. In addition, pingyangmycin was more effective than bleomycin in eliminating lipid deposition in rabbit skin xanthoma.